Stifel Financial Corp Axsome Therapeutics, Inc. Transaction History

Stifel Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$19.91 - $68.26 $8.1 Million - $27.8 Million	-406,935 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$50.63 - $73.5 $6,885 - $9,996	136 Added 0.03%	406,935 $27.5 Million
Q1 2021 May 14, 2021	BUY	$55.91 - $81.44 $42,994 - $62,627	769 Added 0.19%	406,799 $23 Million
Q4 2020 Feb 12, 2021	SELL	$66.31 - $86.52 $35,674 - $46,547	-538 Reduced 0.13%	406,030 $33.1 Million
Q3 2020 Nov 16, 2020	SELL	$68.34 - $85.84 $2,050 - $2,575	-30 Reduced 0.01%	406,568 $29 Million
Q2 2020 Aug 14, 2020	BUY	$49.87 - $98.69 $122,331 - $242,086	2,453 Added 0.61%	406,598 $33.5 Million
Q3 2019 Nov 13, 2019	SELL	$20.24 - $29.16 $7,569 - $10,905	-374 Reduced 0.09%	404,145 $8.18 Million
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $5,034 - $9,630	374 Added 0.09%	404,519 $10.4 Million
Q1 2018 May 11, 2018	SELL	$2.35 - $5.6 $26,164 - $62,350	-11,134 Reduced 2.68%	404,145 $990,000
Q3 2017 Nov 13, 2017	BUY	$4.65 - $6.1 $1.93 Million - $2.53 Million	415,279	415,279 $0

327

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $4.45B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.